The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...

Acceptance follows resolution of third-party fill/finish manufacturing issues FDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: REGN) today announced ...

Acceptance follows resolution of third-party fill/finish manufacturing issues FDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.

The mother of a seven-year-old with a life-threatening blood disorder says despite treatments being the same as cancer, they ...

PLC ("TC BioPharm" or the "Company")  a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the first ...

KYZATREX is a controlled substance (CIII) because it contains testosterone. It is not known if KYZATREX is safe or effective in males younger than 18 years old. Improper use may affect bone growth in ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Rainwater Prizes honor researchers worldwide who are advancing discoveries for diseases caused by tau protein accumulations ...

KalVista Pharmaceuticals, Inc. , today announced the presentation of novel data related to long-term prophylaxis and sebetralstat at the Western Society of Allergy, Asthma & Immunology (WSAAI) 2025 ...

read the label or ask someone at the store. If you consume beer yeast or active dry yeast instead of brewer's yeast, call your healthcare provider right away. It may cause digestion problems as the ...

Developing effective treatments and understanding how the mechanism of the immune system have always been challenging for ...